Navigation Links
ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
Date:12/9/2008

CAMBRIDGE, United Kingdom and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that its U.K.-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed a Long-term Supply Agreement (the "Agreement") with a world-leading European Biopharmaceutical company estimated to be worth up to $35 M over the next six years, with first shipment delivery starting this quarter. This Agreement will provide access to one of ProMetic's proprietary affinity adsorbents for incorporation into this company's manufacturing process.

"This agreement provides further evidence of the underlying growth in the demand for ProMetic's proprietary affinity adsorbents," commented Dr. Steve Burton, PBL's Chief Executive Officer. Dr. Burton added: "Due to reasons of client confidentiality the terms of the Agreement and the name of ProMetic's partner remain undisclosed."

"More and more biopharmaceutical products that have received or are expecting to receive approval from the regulatory agencies such as the Food and Drug Administration or the European Medicines Agency are now manufactured using ProMetic's affinity adsorbent products," stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. "ProMetic's affinity adsorbent products are therefore locked into the regulated manufacturing processes of these biopharmaceuticals and represent long-term recurring and growing annuity revenues for the Company," concluded Mr. Laurin.

About ProMetic BioSciences Ltd

Using its unique and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and manufacture of robust affinity separation materials which provide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured according to a strict quality system based on good manufacturing practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle of Man, which completed a (pnds stlg)1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, U.K.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.


'/>"/>
SOURCE Prometic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
2. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
3. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
4. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
5. Prometic provides information for its Annual and Special Meeting of Shareholders
6. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
7. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
8. Prometic to present at the American Chemical Society
9. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
10. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
11. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... and building management solutions headquartered in Aurora, Ohio, announced the opening of their ... North Carolina, the newly constructed facility is home to 200 employees focused on ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... report "Biomarkers - Technologies, Markets and Companies" to their ... , , ... biomarkers and their discovery using various -omics technologies such as proteomics ... biomarkers and new tests are also based on biomarker. ...
(Date:12/5/2016)... 2016 According to the ... Products (Consumable, Instruments, Automated Cell Expansion System), Cells ... Cell Research, Cancer, and Cell-Based Research), End-users (Biopharmaceutical ... Global Revenue, Trends, Growth, Share, Size and Forecast ... global cell expansion market is expected to reach ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):